Somatization
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with the control group, the SCL-90 test scores of pregnant women in the intervention group were significantly lower in the following five factors: somatization, interpersonal sensitivity, depression, anxiety and fear (p<0.05).
|
31714444 |
2020 |
Somatization
|
0.100 |
Biomarker
|
disease |
BEFREE |
The comparison of the patient and control groups based on SCL-90-R findings demonstrated that the patient group scores in somatization, anxiety (p = 0.000), depression (p = 0.003), anger (p = 0.02), interpersonal sensitivity (p = 0.006), phobia (p = 0.001), paranoid thoughts (p = 0.012), psychosis (p = 0.031) subscales and additional subscale (p = 0.014) and general symptom index (p = 0.001) scores were higher.
|
30472336 |
2019 |
Somatization
|
0.100 |
Biomarker
|
disease |
BEFREE |
Symptoms of anxiety and depression were assessed by the Hopkins Symptom Checklist-25 (HSCL-25), somatization was assessed by the Somatization Subscale of the Symptom-Checklist-90 (SCL-90), and the number of witnessed and experienced trauma was assessed by the Posttraumatic Diagnostic Scale (PDS/HTQ).
|
31088419 |
2019 |
Somatization
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The effect size statistics identified somatization in both BSI-18 and SCL-90-R as the most prevalent and intense symptom of psychological distress.
|
30017779 |
2019 |
Somatization
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the various SCL-90-R or SCL-28 subscales we identified from the clinimetric analysis that the somatization, anxiety, phobic anxiety, psychoticism, and neurasthenia (apathy), as well as the SCL-90-R GSI, were the most impaired psychiatric syndromes reaching a clinically significant effect size above 0.80, whereas the total SCL-28 GSI obtained an effect size of just 0.80.
|
29100973 |
2018 |
Somatization
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no clinically significant difference (effect size = <0.50) in the SCL-90-R total score between the pre-surgical and the healthy controls samples, although pre-surgical patients had lower mean scores compared to the healthy controls in all subscales except somatization (effect size = -0.22).
|
29022751 |
2018 |
Somatization
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with control women, women with PCOS reported significantly higher scores on SCL-90-R scales of somatization, anxiety, hostility, psychoticism, overall psychological distress and a number of symptoms.
|
28385114 |
2018 |
Somatization
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with Chinese normative data taken from literature, patients with PKD exhibited significantly higher (worse) scores across all SCL-90-R subscales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism; P= 0.000 for all) and significantly lower (worse) scores of five domains in WHOQoL-100 (physical domain, psychological domain, independence domain, social relationship domain, and general quality of life; P= 0.000 for all).
|
28836553 |
2017 |
Somatization
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results showed significant positive differences between groups in the first trimester regarding the Somatization subscale of the SCL-90-R (p < .05).
|
28846691 |
2017 |
Somatization
|
0.100 |
Biomarker
|
disease |
BEFREE |
Questionnaires which included State-Trait Anxiety Inventory (STAI), Center for Epidemiological studies-Depression Scale (CED-S), and Symptom Checklist-90-Revised (SCL-90-R) were used to identify anxiety and somatization.
|
29209375 |
2017 |
Somatization
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some evidence was found for good construct validity and criterion validity of the Physical Symptom Checklist (PSC-51) and good construct validity of the Symptom Check-List (SCL-90-R) somatization subscale.
|
29167047 |
2017 |
Somatization
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Global Severity Index (GSI) of SCL-90-R also showed significant difference (1.44 vs 0.46, p = 0.013) as well as the subscales except for somatization.
|
22329956 |
2012 |
Somatization
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Hamilton Rating Scale for Depression and the somatization subscale of the Symptom Checklist-90-Revised (SCL-90-R) were used for psychological assessment.
|
21531467 |
2011 |
Somatization
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatization was evaluated using the respective subscale of the Symptom Checklist SCL-90-R. Six monoaminergic genes were identified showing an involvement in pain perception and somatization according to the literature: COMT, HTR2A, SLC6A2, SLC6A4, DRD4, and TPH1.
|
21838737 |
2011 |
Somatization
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Perceived Risk Questionnaire and validated psychological instruments (POMS-SF; SCL-90-R Somatization subscale) were administered before testing, one week after receiving results and a year later.
|
21737129 |
2011 |